GT, Goodwin act as Japan's Ono buys U.S. drugmaker for $2.4 bln
Greenberg Traurig has represented Japan’s Ono Pharmaceutical Co on its $2.4 billion acquisition of U.S.-based cancer drugmaker Deciphera, which was advised by Goodwin Procter.
According to Reuters, the deal will help Ono expand its oncology portfolio and presence in the United States and Europe.
Deciphera's…
R&T, WongP, Lee & Lee advise on $595 mln TCM deal
Singapore law firms WongPartnership, Lee & Lee and Rajah & Tann (R&T), and R&T’s Malaysian member firm Christopher & Lee Ong have advised traditional Chinese medicine firm Eu Yan Sang International (EYS) and its shareholders on the sale of 86 percent of EYS’ shares.
Skadden advises Cemex on $650 mln Philippines divestment
U.S. law firm Skadden, Arps, Slate, Meagher & Flom has advised Mexico-based multinational building materials company Cemex on the sale of its operations and assets in the Philippines to Dacon Corporation, DMCI Holdings, and Seminara Mining and Power Corporation.
CC, Paul Hastings lead on CR Beverages’ HK IPO
Clifford Chance and Jingtian & Gongcheng are advising China Resources Beverages, the beverage division of the state-owned China Resources Enterprise, on its upcoming Hong Kong IPO, which is expected to raise up to $1 billion. Paul Hastings and Zhong Lun Law Firm are acting for the joint sponsors.
Dentons, CMS, Eng advise on $1.25 bln Europe student housing deal
Dentons has advised Singaporean real estate company Mapletree Investments on its one-billion-pound agreement ($1.25 billion) to acquire 8,192 student housing beds across 19 cities in the UK and Germany from Cuscaden Peak Investments, which was represented ed by CMS, Eng and Co, and Carey Olsen.
CAM, JSA advise on NHAI InvIT $870 mln investment top-up
Indian law firm Cyril Amarchand Mangaldas has advised NHAI InvIT (National Highways Infra Trust) (NHIT), a privately listed infrastructure investment trust, on the $740 million issuance of its units by way of an institutional placement to eligible investors.
Haiwen, CC advise on China TCM's $2 bln take-private deal
Sinopharm Group, an investment consortium led by Sinopharm Group, and China Traditional Chinese Medicine Holdings (China TCM) recently announced a take-private deal for the Hong Kong-listed China TCM through a scheme of arrangement.
Skadden, AMT, MHM, Davis Polk advise on Trial Holding’s $258 mln Japan IPO
Skadden, Arps, Slate, Meagher & Flom and Anderson Mori & Tomotsune have advised Japanese discount-store chain operator Trial Holdings on its $258 million initial public offering on the Tokyo Stock Exchange (TSE), the largest IPO of the year so far.
SAM, HSF guide BAT’s $2.1 bln ITC share sale
Indian law firm Shardul Amarchand Mangaldas & Co and Herbert Smith Freehills have guided British American Tobacco (BAT) on its $2.1 billion strategic divestment in Indian tobacco giant ITC.
SAM, JSA, Trilegal advise on $300 mln Bharat Highways InvIT IPO
Shardul Amarchand Mangaldas has advised the sponsor, investment manager and Bharat Highways InvIT (infrastructure investment trust) on its $300 million initial public offering in India, with J. Sagar Associates advised the lead managers.